AIMT News and Press, Aimmune Therapeutics Inc. From 02/05/20

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it has obtained an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody XmAb ...

Aimmune Gets a Boost as FDA Green Signals Allergy Medication Aimmune Therapeutics ( AIMT ) received FDA nod for its peanut allergy medication Palforzia. This orally administered medication aims to mitigate allergic reactions caused by exposure to peanuts. While it is not designed to be an ...

The U.S. Food and Drug Administration (FDA) approved the first treatment for peanut allergies late Friday, and shares of the company that developed it, Aimmune Therapeutics (NASDAQ: AIMT) rose 6.4% today on the news. Palforzia is the first FDA-approved therapy for any food allergy and b...

Healthcare Pulse The market doesn't like uncertainty. And when you think about healthcare, that uncertainty is immediately magnified. Fundamentally, healthcare couldn't be better positioned, with an aging America, rapidly advancing therapies, a faster-moving FDA, easy access to risk capi...

Artelo Biosciences (NASDAQ: ARTL ) +63%  on NCI grant of $4.2M to Stony Brook University to advance FABP5 inhibitor cancer program. More news on: Artelo Biosciences, Inc., Insmed Incorporated, CTI BioPharma Corp., Stocks on the move, , Read more ...

Aimmune Therapeutics (NASDAQ: AIMT ) +21.7% after-hours on news the Food and Drug Administration approved its Palforzia drug for patients with peanut allergies. More news on: Aimmune Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

More than 1.6 Million Children and Teens in the U.S. are Allergic to Peanuts i,ii Company to Host Conference Call Today at 5:30 p.m. ET Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threateni...

UK-based Allergy Therapeutics ( OTCPK:AGYTF ) announces the publication of positive data on its peanut allergy vaccine candidate in The Journal of Allergy and Clinical Immunology. More news on: Allergy Therapeutics plc, Aimmune Therapeutics, Inc., DBV Technologies S.A., Healthcare sto...

Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha , Apple ...

Aimmune Therapeutics, Inc. ( AIMT ) has risen more than 80% since early September (from under $20 to near $34 now) in anticipation of the FDA approval of Palfrozia – previously known as AR-101 – as the first ever approved treatment for children who suffer from peanut allergies. B...